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OBJECTIVE — We have previously shown that hypogonadotrophic hypogonadism is com-
mon in middle-aged patients with type 2, but not with type 1, diabetes. We have now investi-
gatedthetotalandfreetestosteroneconcentrationsinyoung(aged18–35years)type1andtype
2 diabetic patients.
RESEARCH DESIGN AND METHODS — In this study carried out in a tertiary referral
center, serum concentrations of total and free testosterone were measured in 38 type 1 diabetic
(mean age 26.45  0.89 years) and 24 type 2 diabetic (mean age 27.87  0.97 years) subjects.
ThemeanBMIoftype1andtype2diabeticpatientswas27.411.18and38.552.04kg/m
2,
respectively (P  0.001).
RESULTS — The mean total testosterone concentration of type 1 and type 2 diabetic patients
was22.891.23and11.140.99nmol/l,respectively(P0.001).Themeanfreetestosterone
concentration of type 1 and type 2 diabetic patients was 0.489  0.030 and 0.296  0.022
nmol/l, respectively (P  0.001). Eight of 24 (33%) type 2 diabetic patients had subnormal free
testosterone concentrations (0.225 nmol/l). Using an age-based reference range, 14 of 24
(58%) type 2 diabetic patients had low free testosterone concentrations (0.278 nmol/l). Three
of 38 (8%) type 1 diabetic patients had free testosterone concentrations below the lower limit of
normal(P0.02whencomparedwithtype2diabetes).Luteinizinghormone(LH)andfollicle-
stimulating hormone (FSH) concentrations in type 2 diabetic patients with low free testosterone
concentrations were in the normal range and were similar to those in type 1 diabetic patients.
CONCLUSIONS — Young type 2 diabetic patients have signiﬁcantly lower plasma concen-
trations of total and free testosterone and inappropriately low LH and FSH concentrations with
a very high prevalence of hypogonadotrophic hypogonadism, when compared with type 1
diabetic patients of a comparable age. The potential implications for their sexual and reproduc-
tive function during prime reproductive years are profound.
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W
ehavepreviouslyshownthatpa-
tientswithtype2diabeteshavea
frequent occurrence of hypogo-
nadotrophic hypogonadism, as reﬂected
in low plasma concentrations of testoster-
one and inappropriately low luteinizing
hormone (LH) and follicle-stimulating
hormone (FSH) (1). These studies were
carried out in patients with a mean age of
55 years. Other studies (2,3), also carried
out in middle-aged populations, have
conﬁrmed the frequent occurrence of this
defect in type 2 diabetes. We have also
shown that the prevalence of this defect is
very low in type 1 diabetes (4). In view of
the increasing incidence of obesity and
type 2 diabetes in younger populations
andinchildren,theoccurrenceofthisde-
fect in younger populations needs to be
investigated, since such an abnormality
would affect their sexual function, repro-
ductive capacity, and the quality of life
during their peak reproductive years. In
addition, the lack of testosterone would
also potentially promote further weight
gain and loss of skeletal muscle and
would thus promote insulin resistance
(5–7). In view of the above observations,
we have now hypothesized that younger
patients with type 2 diabetes have signif-
icantly lower testosterone concentrations
and a higher prevalence of low testoster-
one concentrations (hypogonadism)
when compared with patients with type 1
diabetes.
RESEARCH DESIGN AND
METHODS— The study was con-
ducted in the Diabetes Endocrinology
Center of Western New York, a tertiary
referral center afﬁliated with the State
University of New York and Kaleida
Health in Buffalo, New York. This is a
cross-sectional analysis of total and free
testosterone concentrations in 24 type 2
diabetic (mean age 27.87  0.97 years)
and38type1diabetic(meanage26.45
0.89 years) male patients aged between
18 and 35 years. These patients were re-
ferred to our center for management and
control of diabetes. Data were collected
from January 2007 to January 2008. Pa-
tients with a known history of hypogo-
nadism, panhypopituitarism, or chronic
debilitating disease, such as renal failure,
cirrhosis, or HIV, were excluded from the
study.Demographicparameterswerecol-
lected. Fasting blood samples were then
obtainedtomeasureserumtotaltestoster-
one, free testosterone, sex hormone–
binding globulin (SHBG), LH, FSH,
prolactin, and A1C. We evaluate testos-
terone concentrations routinely in dia-
betic patients in view of the high
frequency (one in three) of low testoster-
one concentrations. Informed consent
was therefore not obtained. Health Insur-
ance Portability and Accountability Act
formsweresignedbyallpatients.Thecol-
lected data were kept conﬁdential by the
investigators, and patient identiﬁers were
eliminated from the database once the
master database had been created.
Total testosterone was measured by
solid-phase radioimmunoassay (Coat-A-
Count; Diagnostic Products, Los Angeles,
CA) (normal range 10.4–34.7 nmol/l).
SHBGwastestedatSpecialtyLaboratories
(Santa Monica, CA) by immunochemi-
luminometric assay. LH and FSH were
measured by chemiluminescent immu-
nometric assays. Free testosterone was
calculated from SHBG and testosterone
using the method of Vermeulen and col-
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as low free testosterone (0.225 nmol/l
[6.5 ng/dl] was taken as lower limit of
normal for free testosterone) (10).
Statistical analysis
DataarepresentedasmeansSE.Mann-
Whitney rank-sum test was used to com-
pare nonparametric data, and t test was
usedtocompareparametricdata.Fisher’s
exact test or 
2 test was also used to com-
pare the groups whenever appropriate.
Spearman correlation (for nonparametric
data) and Pearson correlation (for para-
metric data) was used to establish sta-
tistical relationships. P  0.05 was
considered signiﬁcant. Sigma Stat soft-
ware (SPSS, Chicago, IL) was used for
analysis.
RESULTS— Total and free testoster-
one concentrations (11.14  0.99 and
0.296  0.022 nmol/l, respectively) in
type 2 diabetic patients were signiﬁcantly
lower (P  0.001 for both) than the total
and free testosterone concentrations
(22.891.23and0.4890.030nmol/l,
respectively) in type 1 diabetic patients
(Table 1) (Fig. 1). We deﬁned hypogo-
nadism as a low free testosterone concen-
tration. On the basis of usual normal
ranges, 8 of 24 type 2 diabetic patients
werehypogonadal,whereas3of38type1
diabetic patients were hypogonadal (P 
0.001). Two of three hypogonadal type 1
diabetic patients were morbidly obese
(BMI 57 and 41 kg/m
2, respectively),
while one was grossly underweight (BMI
15.8 kg/m
2) and was under investigation
for malabsorption and anorexia nervosa.
Five other patients with obesity and type
1 diabetes had total and free testosterone
concentrations in the middle- to high-
normal range. Since testosterone concen-
trations decline with age, we searched the
literature for information on the concen-
trations of calculated free testosterone in
youngerpatients.Onearticleprovidedin-
formation on the concentrations of total
and free testosterone in men aged 20–29
years (11). Using the range of free testos-
terone cited for the decade 20–29
(0.278–0.777 nmol/l), 14 of 24 type 2
diabetic patients would have subnormal
concentrations and thus would be hy-
pogonadal. All patients except three with
type2diabeteshadaBMI30kg/m
2and
were, therefore, obese. All three had
normal total and free testosterone con-
centrations. Thus, the prevalence of hy-
pogonadism in obese, young subjects
withtype2diabeteswasevenhigher(8of
21 using the usual range and 14 of 21
using the range for young male subjects).
As previously reported, SHBG con-
centrationsweresigniﬁcantlylowerinpa-
tients with type 2 diabetes than in those
withtype1diabetes(4).LHandFSHcon-
centrations in patients with type 2 diabe-
tes were in the normal range and were
therefore inappropriately low. LH, FSH,
and prolactin concentrations in these pa-
tients were similar to those in type 1 dia-
betic patients.
Relationship of testosterone with age
and BMI
Data for both type 1 and type 2 diabetes
were combined to calculate correlation
coefﬁcients. Free and total testosterone
were related to each other (r  0.89, P 
0.001). Free testosterone was negatively
related to age (r  0.39, P  0.01) and
BMI(r0.50,P0.001)(Fig.2).The
relatively small number of subjects in
each group did not allow enough power
tocalculatecorrelationsseparatelyintype
2 and type 1 diabetic patients for each
indexmeasured.However,totaltestoster-
one concentrations were related to LH
(r0.46,P0.036)andFSH(r0.67,
P  0.001) in type 1, but not in type 2,
diabetic patients. Free testosterone con-
centrationswererelatedtoFSH(r0.62,
P  0.01) and had a trend toward a rela-
tionship to LH in type 1 (r  0.39, P 
0.1) but not in type 2 diabetic patients.
LH and FSH concentrations were related
to each other in type 1 (r  0.58, P 
0.01), but not in type 2 (r  0.06, P 
0.79), diabetic patients.
Theethnicityofpatientsismentioned
in Table 1. Caucasians were the majority
group in both type 1 and type 2 diabetes.
Alargerpercentageoftype2diabeticsub-
jects (25%) were African American com-
pared with type 1 diabetic men (5%).
Demographic and hormonal concentra-
tionsoftype2diabeticsubjectsaccording
to their ethnicity are described in Table 2.
The lower free testosterone concentra-
tions of Hispanic men compared with Af-
rican American men can be explained by
the higher age of Hispanic men. The
higher free testosterone concentration of
AfricanAmericanscomparedwithCauca-
sianscouldbeexplainedbythelowerBMI
of African American men (although the
difference not signiﬁcant [P  0.32],
probably due to the small sample size). It
is, however, interesting that none of the
seven African American men in our study
hadalowfreetestosteroneconcentration.
These ﬁndings need to be conﬁrmed in a
Table 1—Comparison of demographics and hormonal concentrations of type 1 and type 2
diabetic patients
Type 2
diabetes
Type 1
diabetes P
n 24 38
Age (years) 27.87  0.97 26.45  0.89 0.37
BMI (kg/m
2) 38.55  2.04 27.41  1.18 0.001
Total testosterone (nmol/l) 11.14  0.99 22.89  1.23 0.001
Free testosterone (nmol/l) 0.296  0.022 0.489  0.030 0.001
% hypogonadal 33% 8% 0.02
SHBG (nmol/l) 19.63  2.41 36.43  2.28 0.001
LH (IU/l) 3.5  0.4 3.79  0.44 0.58
FSH (IU/l) 3.46  0.43 4.54  0.87 0.61
Prolactin (mcg/l) 6.97  0.65 7.44  0.59 0.57
A1C (%) 7.09  0.42 7.73  0.22 0.17
Caucasian (%) 50 92 0.001
African American (%) 25 5 0.001
Hispanic (%) 21 0 0.001
Asian (%) 4 3 0.61
Insulin use 57 100 0.001
Mean insulin dose (units) 72  18 60  4 0.96
Exenatide use % (dose) 21% (6.7  1.7 g) 3% (5  0 g) 0.001
Metformin use  % (dose) 86% (1.6  0.2 g) 7% (2  0g ) 0.001
Sulfonylurea use % (dose) 64% (9  1.4 mg) 0 0.001
Thiazolidinedione use (%) 21 0 0.001
C-peptide (ng/ml) 2.13  0.45 0.36  0.13 0.001
Data are means  SE or percent, unless otherwise indicated.
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type 2 diabetic subjects. A recent epide-
miological survey (12) did not ﬁnd any
relation of ethnicity to testosterone
concentrations.
CONCLUSIONS — Our data show
clearly that the mean total and free testos-
terone concentrations in young patients
with type 2 diabetes are signiﬁcantly
lower than those in patients with type 1
diabetes. Eight of 24 type 2 diabetic pa-
tients had low free testosterone concen-
trations. According to previously
published data, normal free testosterone
concentrations in young men (age 21–29
years) are 0.278–0.777 nmol/l (11). The
mean free testosterone concentration of
type 2 diabetic patients in our study was
0.296 nmol/l. This is clearly low for a
group in its peak reproductive years.
Fourteenof24patientshadfreetestoster-
one concentrations 0.278nmol/l. Thus,
thissmallsampleofyoungerpatientswith
type 2 diabetes had a prevalence of hypo-
gonadism of 33% on the basis of the stan-
dard normal ranges. However, if the
normal range from a study on younger
male subjects aged 20–29 years is used,
14 of 24 (58%) type 2 diabetic subjects
weresubnormal.Consistentwithourpre-
vious data, hypogonadal patients had
inappropriately low LH and FSH concen-
trationsandthushadhypogonadotrophic
hypogonadism (1). It is also noteworthy
that all the eugonadal type 2 diabetic pa-
tients were not obese, and, therefore, the
prevalence of hypogonadotrophic hypo-
gonadism in obese type 2 diabetic pa-
tients was even higher.
Patients with type 1 diabetes, on the
other hand, had much higher total and
freetestosteroneconcentrationsthatwere
comparable with those observed in
younger normal subjects. Three of 38 pa-
tients had subnormal free testosterone
concentrations and therefore were hy-
pogonadal. Two of them were morbidly
obese (BMI 57 and 41.4 kg/m
2, respec-
tively). These patients’ hypogonadal state
could, in part, be attributed to gross obe-
sity.Oneotherpatientwhowasmarkedly
underweight (BMI 15.8 kg/m
2) had sub-
normal total and free testosterone con-
centrations.Hewasbeinginvestigatedfor
malabsorption and anorexia nervosa. The
rest had middle- to high-normal total and
freetestosteroneconcentrationssimilarto
those observed in normal subjects, con-
sistentwiththeirage.Thegroupwithnor-
mal total and free testosterone included
ﬁve other patients with nonmorbid obe-
sity and type 1 diabetes.
Since the association of obesity with
type 2 diabetes led to a greater chance of
developing hypogonadotrophic hypogo-
nadism, and its existence in type 1 diabe-
tes occurred only in association with
morbid obesity, BMI is a major determi-
nant of hypogonadotrophic hypogonad-
ism. It is well known that obesity is
inversely associated with free and total
testosterone concentrations in middle-
aged and elderly men. A recent report
from the Netherlands found a 35.6%
prevalence of hypogonadotrophic hypo-
gonadism in obese men (mean age 58
years). The study population included
type2diabeticmen.Comparisonofprev-
alence of hypogonadotrophic hypogo-
nadismintype2diabeticandnondiabetic
obese men was not available in this pub-
lication. We (1) and others (2) have de-
scribed that the negative association of
Figure 1—Comparison of free testosterone concentrations and their distribution in type 1 and
type 2 diabetic patients. Note that the highest free testosterone concentration in type 2 diabetes is
similar to the mean concentration of type 1 diabetes.
Figure2—InverserelationofBMIwithfreetestosteroneintype1(E)andtype2(F)diabetes.r
0.50; P  0.001.
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in middle-aged (mean age 53–58 years)
type 2 diabetic men. These men have a
high prevalence (33–50%) of hypogona-
dotrophic hypogonadism.
Nielsenetal.(11)examinedtestoster-
one concentrations of 615 nonobese and
70obeseyoungDanishmen(aged20–29
years) in association with subcutaneous
and visceral fat mass, measured by dual-
energy X-ray absorptiometry and mag-
netic resonance imaging. The purpose of
this study was to investigate the impact of
obesity on reference intervals for testos-
terone in young men. The reference in-
terval of plasma free testosterone in
nonobesemenwas0.29–0.78nmol/land
in obese men 0.23–0.67 nmol/l. Total
and bioavailable testosterone concentra-
tions were negatively related to all mea-
sures of fat mass. A total of 23% of obese
youngmenhadsubnormaltotaltestoster-
one concentrations, while 10% had sub-
normaltotalandbioavailabletestosterone
concentrations. Thus, obesity without di-
abetes may be related to hypogonadotro-
phic hypogonadism.
The strength of our current report is
that it describes the prevalence of hy-
pogonadotrophic hypogonadism in
young type 2 diabetic men (aged 18–35
years; mean age 28 years). In addition,
BMI was inversely related to free testos-
terone.Sincetestosteronefallswithage,it
is important to highlight that BMI is neg-
atively associated with hypogonadotro-
phic hypogonadism, even at an early age
in men, and that there is a very high prev-
alence of hypogonadotrophic hypogo-
nadism (58% on the basis of age-matched
control subjects) in young type 2 diabetic
men. Using the reference range for obese
young men (11), the prevalence of hy-
pogonadotrophic hypogonadism in
young type 2 diabetic men is 33%. This
prevalence is higher than the rate of 10%
found in young obese men (11). More fo-
cusedinvestigationsontherelationshipof
obesity, especially visceral adiposity, in
type 2 diabetic men (using imaging
techniques or surrogate clinical mea-
sures such as waist circumference) to
total and free testosterone concentra-
tions are required.
Whileobesitycontributestotheasso-
ciation of type 2 diabetes with hypogona-
dotrophic hypogonadism, the association
is not entirely dependent on obesity. In
our ﬁrst study on type 2 diabetic men, we
found that 31% of lean type 2 diabetic
men also had hypogonadotrophic hypo-
gonadism(1).Itislikelythatfactorsother
thanobesityalsocontributetohypogona-
dotrophic hypogonadism (13). It is pos-
sible that the association is mediated via
insulin resistance. Type 2 diabetic pa-
tients generally have higher insulin resis-
tance, while all obese men are not insulin
resistant. A recent analysis (14) from the
Third National Health and Nutrition Ex-
aminationSurveyshowedthatlowandro-
gens were a risk factor for type 2 diabetes
in men. In multivariable models adjusted
forage,race/ethnicity,andadiposity,men
in the lowest tertile of free testosterone
concentrations were four times more
likely to have type 2 diabetes compared
with men in the third tertile (odds ratio
4.12 [95% CI 1.25–13.55]). Whether
obesity or insulin resistance is the major
determinant of hypogonadotrophic hy-
pogonadism has to be addressed in future
studies, and the pathogenesis of hypogo-
nadotrophic hypogonadism needs to be
deﬁned. It has been suggested that in-
creased aromatase activity in the adipose
tissue may lead to a greater degree of con-
version from testosterone to estradiol and
that the excess of estradiol suppresses the
hypothalamus hypophyseal axis. On the
other hand, it has also been shown that
thedeletionoftheinsulinreceptorgenein
neurons of mice leads to hypogonadotro-
phic hypogonadism. Thus, the insulin-
resistant state in the hypothalamus may
leadtohypogonadotrophichypogonadism.
As previously reported, the concen-
trations of SHBG tended to be low in type
2 diabetic subjects and to be middle to
high normal in type 1 diabetic subjects
(4). Despite corrections made to total tes-
tosterone concentrations on the basis of
SHBG, the concentrations of calculated
free testosterone remained markedly lower
intype2diabetesandrelativelyhighintype
1 diabetes.
These observations have several clin-
ical implications, since low testosterone
concentrations may contribute to the im-
pairment of sexual function, diminished
libido, and erectile dysfunction. Further-
more, the lack of testosterone during
thesecrucialyearsmayleadtodiminished
peak bone mass and the lack of develop-
ment or loss of skeletal muscle (7). In ad-
dition, these patients may develop
increased adiposity and, therefore, may
become more insulin resistant (2,15).
Clearly, patients with type 2 diabetes, es-
pecially if they are obese, need further
focused attention and systematic investi-
gation. This is even more relevant to
youngertype2diabeticpatients.Further-
more, patients with hypogonadotrophic
hypogonadism and type 2 diabetes have
been shown to have very high C-reactive
protein concentrations (16). Thus, they
may be at a heightened risk of atheroscle-
rosis and cardiovascular disease. Indeed,
low testosterone concentrations in male
subjects are known to be associated with
enhanced cardiovascular risk in observa-
tional studies (17,18). A Japanese study
(19) has shown that free testosterone (but
not total testosterone) concentrations are
inversely related to carotid intimal medial
thickness in type 2 diabetic patients.
Sincefreetestosteronewasmeasurebyra-
dioimmunoassayinthatstudy,theseﬁnd-
ingsneedtobeconﬁrmedbyusingamore
reliable assay.
In addition, these patients are also
candidatesforinfertility,sincesubnormal
FSHconcentrationsarelikelytoadversely
affect the development of seminiferous
tubules and spermatogenesis. Indeed, in
twopatientswithhypogonadotrophichy-
pogonadism and type 1 diabetes, we have
found marked oligospermia following se-
men analysis (A. Chandel, S.D., S.T., and
P.D., unpublished observations). The
treatment plans for such patients should
include not only testosterone therapy but
Table2—Relationshipofethnicitytoage,BMI,andhormoneconcentrationsintype2diabetic
men
Caucasian Hispanic African American
n 12 5 7
Age (years) 27.17  1.32 31.78  0.73* 26.28  2†
BMI (kg/m
2) 41.08  3.39 35.38  2.72 36  2.84
Total testosterone (nmol/l) 9.89  1.63 11.36  1.23 13.13  1.65
SHBG (nmol/l) 16.99  3.25† 30.2  6.12 16.21  2.68†
Free testosterone (nmol/l) 0.275  0.028 0.215  0.027 0.388  0.032*†
% hypogonadal 36 60 0
Data are means  SD or percent, unless otherwise indicated. *P  0.05 vs. Caucasian; †P  0.05 vs.
Hispanic.
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therapy in order to restore fertility.
In conclusion, young patients with
type 2 diabetes have signiﬁcantly lower
plasma concentrations of total and free
testosterone,withinappropriatelylowLH
and FSH concentrations, when compared
with type 1 diabetic patients of a compa-
rable age. The prevalence of absolute or
relative hypogonadism is also markedly
higher in this group. There is an inverse
relationship between BMI and total and
free testosterone concentrations. Type 2
diabeticpatientswithobesityappeartobe
atagreaterriskofhypogonadotrophichy-
pogonadism than those without. The
implications for their sexual and repro-
ductive function, as well as the underly-
ing defect of insulin resistance, are
profound. This area requires careful fur-
ther assessment and investigation.
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